Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes.

Authors

Yohann Loriot

Yohann Loriot

Gustave Roussy, INSERMU981, Université Paris-Saclay, Villejuif, France

Yohann Loriot , Shilpa Gupta , Thomas Powles , Petros Grivas , Daniel P. Petrylak , Karin Tyroller , Natalia Jacob , Jason Hoffman , Joaquim Bellmunt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02603432

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4567)

DOI

10.1200/JCO.2024.42.16_suppl.4567

Abstract #

4567

Poster Bd #

262

Abstract Disclosures